Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - aneemia, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited - ruxolitiniib (fosfaadina) - myeloproliferative disorders; polycythemia vera; graft vs host disease - antineoplastilised ained - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polycythaemia vera (pv)jakavi on näidustatud ravi täiskasvanud patsientidel, kellel polycythaemia vera, kes on resistentsed või sallimatu hydroxyurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.

Eesti - eesti - Ravimiamet

bluefish pharmaceuticals ab - hüdroksüsiin - õhukese polümeerikattega tablett - 25mg 20tk

Eesti - eesti - Ravimiamet

icn polfa rzeszów s.a. - hüdroksüsiin - kaetud tablett - 25mg 60tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

vifor fresenius medical care renal pharma france - sucroferric oxyhydroxide - hyperphosphatemia; renal dialysis - narkootikumide raviks hyperkalemia ja hyperphosphatemia - velforon on näidustatud hemodialüüsi (hd) või peritoneaaldialüüsi (pd) täiskasvanud kroonilise neeruhaiguse (ckd) patsientide seerumi fosforisisalduse kontrollimiseks.. velphoro is indicated for the control of serum phosphorus levels in paediatric patients 2 years of age and older with ckd stages 4-5 (defined by a glomerular filtration rate.

Eesti - eesti - Ravimiamet

bayer animal health gmbh - tsüflutriin - kriipsulahus - 10mg 1ml 500ml 1tk

Eesti - eesti - Ravimiamet

norbrook laboratories (ireland) limited - deltametriin - täpilahus - 10mg 1ml 250ml 1tk; 10mg 1ml 1000ml 1tk; 10mg 1ml 500ml 2tk; 10mg 1ml 500ml 1tk

Eesti - eesti - Ravimiamet

bimeda animal health limited - deltametriin - kriipsulahus - 10mg 1ml 1000ml 1tk; 10mg 1ml 2500ml 1tk; 10mg 1ml 500ml 1tk; 10mg 1ml 250ml 1tk

Eesti - eesti - Ravimiamet

virbac - deltametriin - kriipsulahus - 10mg 1ml 2500ml 1tk; 10mg 1ml 1000ml 1tk; 10mg 1ml 4500ml 1tk; 10mg 1ml 500ml 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

sanofi pasteur europe - filamentous haemagglutinin, haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate), hepatitis b surface antigen, pertussis toxoid, poliovirus (inactivated) type 1 (mahoney strain) produced on vero cells, poliovirus (inactivated) type 2 (mef-1 strain) produced on vero cells, poliovirus (inactivated) type 3 (saukett strain) produced on vero cells, tetanus protein, tetanus toxoid adsorbed on aluminium hydroxide, hydrated, diphtheria toxoid - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vaktsiinid - hexyon (dtap-ipv-hb-hib) on näidustatud esmaseks ning imikutele ja väikelastele alates kuue nädala vanused difteeria, teetanuse, läkaköha, b-hepatiidi, poliomüeliidi ja haemophilus influenzae tüüp b (hib) poolt põhjustatud invasiivse haiguse vastu. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.